References: 
References
1. Cuesta MJ, Gil P, Artamendi M, et al. Premorbid personality and psychopathological dimensions in first-episode psychosis. Schizophr Res. 2002;58:273-280.
2. Krauthammer C, Klerman GL. Secondary mania: manic syndromes associated with antecedent physical illnesses or drugs. Arch Gen Psychiatry. 1978;35: 1333-1339.
3. Fava GA, Kellner R. Prodromal symptoms in affective disorders. Am J Psychiatry. 1991;148:823-830.
4. Lam D, Wong G, Sham P. Prodromes, coping strategies and course of illness in bipolar affective disorder--a naturalistic study. Psychol Med. 2001;31:1397-1402.
5. Miklowitz DJ. Longitudinal outcome and medication noncompliance among manic patients with and without mood-incongruent psychotic features. J Nerv Ment Dis. 1992;180:703-711.
6. Lieberman PB, Strauss JS. The recurrence of mania: environmental factors and medical treatment. Am J Psychiatry. 1984;141:77-80.
7. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61(suppl 9):47-51.
8. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry. 1999;156:181-189.
9. Beck AT, Steer RA, Kovacs M, Garrison B. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry. 1985;142:559-563.
10. Swann AC, Dougherty DM, Pazzaglia PJ, et al. Increased impulsivity associated with severity of suicide attempt history in patients with bipolar disorder. Am J Psychiatry. 2005;162:1680-1687.
11. Simon TR, Swann AC, Powell KE, et al. Characteristics of impulsive suicide attempts and attempters. Suicide Life Threat Behav. 2001;32(suppl 1):30-41.
12. Busch KA, Fawcett J, Jacobs DG. Clinical correlates of inpatient suicide. J Clin Psychiatry. 2003;64:14-19.
13. Barratt ES, Patton JH. Impulsivity: cognitive, behavioral, and psychophysiological correlates. In: Zuckerman M, ed. Biological Basis of Sensation-Seeking, Impulsivity, and Anxiety. Hillsdale, NJ: Lawrence Erlbaum Associates; 1983:77-116.
14. Peterson LG, Peterson M, O'Shanick G, Swann AC. Violent suicide attempts: lethality of method vs intent. Am J Psychiatry. 1985;142:228-231.
15. Goodman LA, Salyers MP, Mueser KT, et al. Recent victimization in women and men with severe mental illness: prevalence and correlates. J Trauma Stress. 2001; 14:615-632.
16. Simon TR, Anderso M, Thompson MP, et al. Assault victimization and suicidal ideation or behavior within a national sample of US adults. Suicide Life Threat Behav. 2002;32:42-50.
17. Dilsaver SC, Chen YR, Swann AC, et al. Suicidality in patients with pure and depressive mania. Am J Psychiatry. 1995;151:1312-1315.
18. Swann AC, Stokes PE, Secunda S, et al. Depressive mania vs agitated depression: biogenic amine and hypothalamic-pituitary-adrenocortical function. Biol Psychiatry. 1994;35:803-813.
19. Kotin J, Goodwin FK. Depression during mania: clinical observations and theoretical implications. Am J Psychiatry. 1971;129:55-62.
20. Schweizer E, Dever A, Clary C. Suicide upon recovery from depression. A clinical note. J Nerv Ment Dis. 1988; 176:633-636.
21. Craig TJ, Ye Q, Bromet EJ. Mortality among first- admission patients with psychosis. Compr Psychiatry. 2006;47:246-251.
22. Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol. 1996;16(suppl 1):32S-47S.
23. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf. 1993;8:186-212.
24. Sachs GS, Yan LJ, Swann AC, Allen MH. Integration of suicide prevention into outpatient management of bipolar disorder. J Clin Psychiatry. 2001;62(suppl 25):3-11.
25. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affective Disord. 1998;51:333-343.
26. Allen MH, Currier GW, Hughes DH, et al. The expert consensus guideline series. Treatment of behavioral emergencies. Postgrad Med. 2001;(spec no):1-88.
27. Allen MH, Currier GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry. 2004;26:42-49.
28. Cure S, Rathbone J, Carpenter S. Droperidol for acute psychosis. Cochrane Database Syst Rev. 2004;4: CD002830.
29. Gerlach J, Larsen EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl. 1999;395:113-137.
30. Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother. 2005;5:297-307.
31. Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine. Am J Psychiatry. 1999;156:796-797.
32. Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry 1998;59(suppl 12):17-22.
33. Chengappa KN, Levine J, Ulrich R, et al. Impact of risperidone on seclusion and restraint at a state psychiatric hospital. Can J Psychiatry. 2000;45:827-832.
34. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry. 2000;57:841-849.
35. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741-748.
36. Brook S. A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia. Hum Psychopharmacol. 2000; 15:521-524.
37. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66: 111-121.
38. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
39. Allen MH, Currier GW, Carpenter D, et al. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005; 11(suppl 1):5-108.
40. Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs. 2003;63:493-512.
41. Chengappa KN, Vasile J, Levine J, et al. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophr Res. 2002;53:1-6.
42. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law. 1995;23:607-611.
43. Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or halo-peridol. J Clin Psychopharmacol. 2004;24:225-228.
44. Fehr BS, Ozcan ME, Suppes T. Low doses of cloza-pine may stabilize treatment-resistant bipolar patients. Eur Arch Psychiatry Clin Neurosci. 2005;255:10-14.
45. Swann AC, Bowden CL, Calabrese JR, et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002;26:530-536.
46. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186-1197.
47. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry. 2000;157:818-820.
48. Steiner H, Petersen ML, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: a random- ized controlled clinical trial. J Clin Psychiatry. 2003;64: 1183-1191.
49. Vitiello B, Behar D, Hunt J, et al. Subtyping aggression in children and adolescents. J Neuropsychiatry Clin Neurosci. 1990;2:189-192.
50. Kruger S, Braunig P. Intravenous valproic acid in the treatment of severe catatonia. J Neuropsychiatry Clin Neurosci. 2001;13:303-304.
51. McElroy SL, Keck PE, Jr, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry. 1996;57:142-146.
52. Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol. 1997;17:341-349.
53. Chatham-Showalter PE. Carbamazepine for combativeness in acute traumatic brain injury. J Neuropsychiatry Clin Neurosci. 1996;8:96-99.
54. Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry. 2000;8:45-63.
55. Devarajan S, Dursun SM. Aggression in dementia with lamotrigine treatment. Am J Psychiatry. 2000;157: 1178.
56. Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia. 1998;39:280-282.
57. Little JD, Taghavi EH. Disinhibition after lorazepam augmentation of antipsychotic medication. Am J Psychiatry. 1991;148:1099-1100.
58. Ben Porath DD, Taylor SP. The effects of diazepam (valium) and aggressive disposition on human aggression: an experimental investigation. Addict Behav. 2002; 27:167-177.
59. Hollister LE. Interactions between alcohol and benzodiazepines. Recent Dev Alcohol. 1990;8:233-239.
60. Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry. 1989;146:1598-1601.
61. Janicak PG, Sharma RP, Easton M, et al. A double-blind, placebo-controlled trial of clonidine in the treatment of acute mania. Psychopharmacol Bull. 1989; 25: 243-245.
62. Haspel T. Beta-blockers and the treatment of aggression. Harv Rev Psychiatry. 1995;2:274-281.
63. Pozzi G, Conte G, De Risio S. Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study. Drug Alcohol Depend. 2000;59:287-294.
64. Allan ER, Alpert M, Sison CE, et al. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J Clin Psychiatry. 1996;57:455-459.
65. Caspi N, Modai I, Barak P, et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol. 2001;16:111-115.
66. Grof P, Grof E. Varieties of lithium benefit. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:689-696.
67. Fava M. Psychopharmacologic treatment of pathol- ogic aggression.. Psychiatr Clin North Am. 1997;20: 427-451.
68. Frye MA, Calabrese JR, Reed ML, et al. Use of health care services among persons who screen positive for bipolar disorder. Psychiatr Serv. 2005;56:1529-1533.
69. Ernst CL, Bird SA, Goldberg JF, Ghaemi SN. The prescription of psychotropic medications for patients discharged from a psychiatric emergency service. J Clin Psychiatry. 2006;67:720-726.
70. Soltis RP, Cook JC, Gregg AE, Sanders BJ. Interaction of GABA and excitatory amino acids in the basolateral amygdala: role in cardiovascular regulation. J Neurosci. 1997;17:9367-9374.
71. Benes FM. The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. J Psychiatr Res. 1997;31:257-275.
72. Juhl RP, Tsuang MT, Perry PJ. Concomitant administration of haloperidol and lithium carbonate in acute mania. Dis Nerv Syst. 1977;38:675-676.
73. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev. 2002;3:CD001258.
74. Wassef AA, Hafiz NG, Hampton D, Molloy M. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol. 2001;21:21-26.
75. Lancee WJ, Gallop R, McCay E, Toner B. The relationship between nurses' limit-setting styles and anger in psychiatric inpatients. Psychiatr Serv. 1995;46:609-613.
76. Melle I, Friis S, Hauff E, et al. The importance of ward atmosphere in inpatient treatment of schizophrenia on short-term units. Psychiatr Serv. 1996;47:721-726.
77. Dilsaver SC, Chen YR, Swann AC, et al. Suicidality, panic disorder, and psychosis in bipolar depression, depressive-mania, and pure mania. Psychiatry Res. 1997; 73:47-56.
78. Coryell W, Leon AC, Turvey C, et al. The significance of psychotic features in manic episodes: a report from the NIMH collaborative study. J Affect Disord. 2001;67: 79-88.
79. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149:733-745.
80. Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and g-hydroxybutyrate. Am J Health Syst Pharm. 2002;59:1067-1076.
81. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003;33:15-21.
82. Freedman R, Schwab PJ. Paranoid symptoms in patients on a general hospital psychiatric unit. Implications for diagnosis and treatment. Arch Gen Psychiatry. 1978; 35:387-390.
83. Dalton EJ, Cate-Carter TD, Mundo E. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord. 2003;5:58-61.
84. Links PS, Heslegrave RJ, Mitton JE, et al. Borderline personality disorder and substance abuse: consequences of comorbidity. Can J Psychiatry. 1995;40:9-14.
85. Beck AT, Steer RA, Trexler LD. Alcohol abuse and eventual suicide: a 5- to 10-year prospective study of alcohol-abusing suicide attempters. J Stud Alcohol. 1989; 50:202-209.
86. Fishbein DH, Herman-Stahl M, Eldreth D, et al. Mediators of the stress-substance-use relationship in urban male adolescents. Prev Sci. 2006;7:113-126.
87. Sher L, Oquendo MA, Galfalvy HC, et al. The relationship of aggression to suicidal behavior in depressed patients with a history of alcoholism. Addict Behav. 2005; 30:1144-1153.
88. King EA, Baldwin DS, Sinclair JM, et al. The Wessex Recent In-Patient Suicide Study, 1. Case-control study of 234 recently discharged psychiatric patient suicides. Br J Psychiatry. 2001;178:531-536.
89. Beck AT, Brown G, Berchick RJ, et al. Relationship between hopelessness and ultimate suicide: a replication with psychiatric outpatients. Am J Psychiatry. 1990;147: 190-195.
90. Beck AT, Brown GK, Steer RA, et al. Suicide ideation at its worst point: a predictor of eventual suicide in psychiatric outpatients. Suicide Life Threat Behav. 1999;29: 1-9.
91. Brent DA, Oquendo M, Birmaher B, et al. Familial pathways to early-onset suicide attempt: risk for suicidal behavior in offspring of mood-disordered suicide attempters. Arch Gen Psychiatry. 2002;59:801-807.
92. Scocco P, Marietta P, Tonietto M, et al. The role of psychopathology and suicidal intention in predicting suicide risk: a longitudinal study. Psychopathology. 2000;33: 143-150.
93. Koller G, Preuss UW, Bottlender M, et al. Impulsivity and aggression as predictors of suicide attempts in alcoholics. Eur Arch Psychiatry Clin Neurosci. 2002;252: 155-160.
94. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf. 2000;22:195-214.